Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Wednesday, December 31, 2025.
Limited history available
MOBI Return on Equity (ROE) has fewer than three reported periods, so a trend chart would be misleading.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
N/A
RETURN ON EQUITY (ROE) AVG 3Y
N/A
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Mobia Medical, Inc. Common Stock
Market Cap
$309.34M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$305.66M
Return on Equity (ROE)
-25.73%
TTM Avg
-32.35%
3Y Avg
-2448.72%
5Y Avg
-1749.34%
Market Cap
$319.27M
Return on Equity (ROE)
-226.56%
TTM Avg
-87.78%
3Y Avg
-55.09%
5Y Avg
-55.09%
Market Cap
$297.62M
Return on Equity (ROE)
-135.50%
TTM Avg
-129.54%
3Y Avg
-84.04%
5Y Avg
-77.00%
Market Cap
$322.30M
Return on Equity (ROE)
-41.02%
TTM Avg
-44.84%
3Y Avg
-46.96%
5Y Avg
-38.83%
Market Cap
$296.20M
Return on Equity (ROE)
-56.36%
TTM Avg
-35.98%
3Y Avg
25430.43%
5Y Avg
20391.58%
Market Cap
$291.68M
Return on Equity (ROE)
-16.18%
TTM Avg
-23.55%
3Y Avg
59.17%
5Y Avg
22.66%
Market Cap
$288.68M
Return on Equity (ROE)
-49.11%
TTM Avg
-50.02%
3Y Avg
-153.47%
5Y Avg
-149.41%
Market Cap
$332.63M
Return on Equity (ROE)
-86.10%
TTM Avg
-112.93%
3Y Avg
-76.30%
5Y Avg
-62.48%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mobia Medical, Inc. Common Stock (MOBI) | $309.34M | N/A | N/A | N/A | N/A |
| Benitec Biopharma Inc. (BNTC)vs › | $305.66M | -25.73% | -32.35% | -2448.72% | -1749.34% |
| CapsoVision, Inc. (CV)vs › | $319.27M | -226.56% | -87.78% | -55.09% | -55.09% |
| Larimar Therapeutics, Inc. (LRMR)vs › | $297.62M | -135.50% | -129.54% | -84.04% | -77.00% |
| C4 Therapeutics, Inc. (CCCC)vs › | $322.30M | -41.02% | -44.84% | -46.96% | -38.83% |
| BridgeBio Oncology Therapeutics Inc. (BBOT)vs › | $296.20M | -56.36% | -35.98% | 25430.43% | 20391.58% |
| Standard BioTools Inc. (LAB)vs › | $291.68M | -16.18% | -23.55% | 59.17% | 22.66% |
| Abeona Therapeutics Inc. (ABEO)vs › | $288.68M | -49.11% | -50.02% | -153.47% | -149.41% |
| Cabaletta Bio, Inc. (CABA)vs › | $332.63M | -86.10% | -112.93% | -76.30% | -62.48% |
| Indaptus Therapeutics, Inc. (INDP)vs › | $284.25M | -135.62% | -521.17% | -307.05% | 43.03% |
ROE
N/A
ROA
-96.6%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | 30.84% |
